These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9536285)

  • 1. p53 mutations in multiple myeloma.
    Paydaś S; Sahin B; Seyrek E; Zorludemir S
    Mol Pathol; 1997 Dec; 50(6):329. PubMed ID: 9536285
    [No Abstract]   [Full Text] [Related]  

  • 2. p53 gene mutations in multiple myeloma.
    Owen RG; Davis SA; Randerson J; Rawstron AC; Davies F; Child JA; Jack AS; Morgan GJ
    Mol Pathol; 1997 Feb; 50(1):18-20. PubMed ID: 9208809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees.
    Willems PM; Kuypers AW; Meijerink JP; Holdrinet RS; Mensink EJ
    Leukemia; 1993 Jul; 7(7):986-91. PubMed ID: 8321049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and RAS gene mutations in multiple myeloma.
    Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
    Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the p53 gene in human myeloma cell lines.
    Mazars GR; Portier M; Zhang XG; Jourdan M; Bataille R; Theillet C; Klein B
    Oncogene; 1992 May; 7(5):1015-8. PubMed ID: 1373872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular analysis of multiple myeloma cells].
    Yasuga Y; Hirosawa S
    Nihon Rinsho; 1995 Mar; 53(3):564-7. PubMed ID: 7699886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of TP53 mutation in myeloma.
    Chng WJ; Price-Troska T; Gonzalez-Paz N; Van Wier S; Jacobus S; Blood E; Henderson K; Oken M; Van Ness B; Greipp P; Rajkumar SV; Fonseca R
    Leukemia; 2007 Mar; 21(3):582-4. PubMed ID: 17215851
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased risk for cancer in multiple myeloma patients and their first-degree relatives.
    Varkonyi J; Kovalszky I; Nemeth A; Demeter J; Raposa T
    Haematologia (Budap); 2001; 31(1):45-50. PubMed ID: 11345403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codon 72 polymorphism of TP53 gene is a novel prognostic marker for therapy in multiple myeloma.
    Hattori Y; Ikeda Y; Suzuki Y; Ichikawa D; Matsushita M
    Br J Haematol; 2014 Jun; 165(5):728-31. PubMed ID: 24611901
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
    Chang H; Sloan S; Li D; Keith Stewart A
    Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
    Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; Gutiérrez NC
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance.
    Newcomb EW
    Leuk Lymphoma; 1995 Apr; 17(3-4):211-21. PubMed ID: 8580789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of multiple myeloma.
    Drach J; Kaufmann H; Urbauer E; Schreiber S; Ackermann J; Huber H
    J Cancer Res Clin Oncol; 2000 Aug; 126(8):441-7. PubMed ID: 10961386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
    Corradini P; Inghirami G; Astolfi M; Ladetto M; Voena C; Ballerini P; Gu W; Nilsson K; Knowles DM; Boccadoro M
    Leukemia; 1994 May; 8(5):758-67. PubMed ID: 8182933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS mutations - for better or for worse in multiple myeloma?
    Leich E; Steinbrunn T
    Leuk Lymphoma; 2016; 57(1):8-9. PubMed ID: 26430811
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
    Mangiacavalli S; Pochintesta L; Cocito F; Pompa A; Bernasconi P; Cazzola M; Corso A
    Br J Haematol; 2013 Aug; 162(4):555-8. PubMed ID: 23718846
    [No Abstract]   [Full Text] [Related]  

  • 17. GSTM1 and codon 72 P53 polymorphism in multiple myeloma.
    Ortega MM; Honma HN; Zambon L; Lorand-Metze I; Costa FF; De Souza CA; Lima CS
    Ann Hematol; 2007 Nov; 86(11):815-9. PubMed ID: 17653713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma.
    Wavre A; Baur AS; Betz M; Mühlematter D; Jotterand M; Zaman K; Ketterer N
    Neuro Oncol; 2007 Jul; 9(3):370-2. PubMed ID: 17522337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathogenesis of multiple myeloma.
    Tonon G
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):985-1006, vii. PubMed ID: 17996585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.